GUD — Knight Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMid CapNeutral

Annual cashflow statement for Knight Therapeutics, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.

	2021 December 31st	C2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	15.7	-29.9	-16.8	4.33	-5.37
Depreciation
Deferred Taxes
Non-Cash Items	-9.33	37.9	38.4	1.71	19.7
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-2.01	-8.49	-26.9	-19.6	1.89
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Cash from Operating Activities	44.6	45	35.9	36.3	69
Capital Expenditures	-224	-25.8	-9.96	-31.5	-33.7
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	119	-37.3	39.3	48.4	-41.5
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-105	-63.1	29.3	17	-75.2
Financing Cash Flow Items	0.297	-4.18	-9.5	-7.2	-6.87
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-78.3	-2.76	-81	-33.5	5.41
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-144	-14.3	-12.9	21.3	-3.66